In Q3 FY2021, Savara reported no revenue, a net loss of $37.3 million, and an operating loss of $39.0 million. Diluted EPS was -$0.15. Year-over-year, net income decreased by 40%, operating income by 37%, and EPS by 25%.
•Revenue was $0, down 100% year-over-year.
•Net loss of $37.3 million, 40% wider than prior year.
•Operating loss of $39.0 million, 37% worse year-over-year.
•Diluted EPS of -$0.15, a 25% decline.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Savara Inc., a clinical stage biopharmaceutical company focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Founded in 2007, Savara is headquartered in Langhorne, Pennsylvania.
Savara Inc. is a clinical stage biopharmaceutical company focused on rare respiratory diseases in the United States. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF), currently in Phase 3 development for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP). The company aims to address unmet medical needs in rare lung conditions.
Where is Savara Inc. listed and what currency does it trade in?
Savara Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol SVRA. Its shares are traded in US dollars (USD), reflecting its primary listing in the United States.
What sector and industry does Savara Inc. operate in?
Savara Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical stage biopharmaceutical company, it focuses on developing therapies for rare respiratory diseases, which falls under the broader biotechnology and pharmaceutical research and development category.
Where is Savara Inc. headquartered and what markets does it serve?
Savara Inc. is headquartered in Langhorne, Pennsylvania, United States. The company primarily serves the US market, as indicated by its focus on rare respiratory diseases within the country. Its operations are centered on clinical development and regulatory activities in the US.
What is Savara Inc.'s lead product candidate and its stage of development?
Savara Inc.'s lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF). It is currently in Phase 3 development for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung disease. The company is advancing this candidate through clinical trials to seek regulatory approval.